GSK PLC LS-,3125
[WKN: A3DMB5 | ISIN: GB00BN7SWP63]
Aktienkurse
16,307€ 2,00%
Echtzeit-Aktienkurs GSK PLC LS-,3125
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

GSK Aktie: Story nicht wesentlich verändert

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät in…

GSK Aktie: Das ist ein Paukenschlag!

Kulmbach (www.aktiencheck.de) - GSK-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Does GSKs RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

GSK: Does RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

Does GSKs RSV jab work too well?

GSK PLCs respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by…

GSK cancer drugs fast-tracked by Chinese

GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has…

GSK sees positive COPD trial results

GSK PLC (LSE:GSK, NYSE:GSK) announced positive results from a Phase III clinical trial, MATINEE, evaluating Nucala (mepolizumab) in chronic obstructive...…

GSK wins Illinois Zantac court battle

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury…

GSK wins Illinois court battle

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury…

GSK: Impfstoffsegment enttäuscht - Aktienanalyse

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…